Overview

Tolvaptan for Advanced or Refractory Heart Failure

Status:
Terminated
Trial end date:
2020-06-30
Target enrollment:
Participant gender:
Summary
This study will clarify the clinical usefulness of Tolvaptan therapy in patients with complicated acute decompensated heart failure and hyponatremia (low blood sodium).
Phase:
Phase 4
Details
Lead Sponsor:
University of Calgary
Collaborator:
Otsuka Canada Pharmaceutical Inc.
Treatments:
Diuretics
Tolvaptan